The lysosome among targets of metformin: New anti-inflammatory uses for an old drug?

Expert Opinion on Therapeutic Targets

Volumn 14, Issue 5, 2010, Pages 467-478

  Lockwood, Thomas D ^a  

^a WRIGHT STATE UNIVERSITY   (United States)

Author keywords

Cathepsin B; Chloroquine; Diabetes; Inflammation; Lysosome; Metformin; Nano pharmacology; Zinc

Indexed keywords

BIGUANIDE; CATHEPSIN B; CHLOROQUINE; CYSTEINE PROTEINASE; METFORMIN; ZINC ION;

ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG ANTAGONISM; DRUG MECHANISM; DRUG POTENCY; DRUG POTENTIATION; HEART MUSCLE; LYSOSOME; NONHUMAN; PROTEIN DEGRADATION; RAT;

ANIMALS; ANTI-INFLAMMATORY AGENTS; LYSOSOMES; METFORMIN; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77951140654     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728221003774135     Document Type: Article

References (75)

1. Halapas A, Armakolas A, Koutsilieris M. Autophagy: a target for therapeutic interventions in myocardial pathophysiology. Expert Opin Ther Targets 2008;12:1509-1522
2. Goldstein OG, Hajiaghamohseni LM, Amria S, et al. Gamma-IFN- induciblelysosomal thiol reductase modulates acidic proteases and HLA class II antigen processing in melanoma. Cancer Immunol Immunother 2008;57:1461-1470
3. Mocchegiani E, Giacconi R, Malavolta M. Zinc signalling and subcellular distribution: emerging targets in type 2 diabetes. Trends Mol Med 2008;14:419-428
4. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007;20:160-174
5. Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. Ann Rheum Dis 2010;69:20-28
6. Wibo M, Poole B. Protein degradation in cultured cells.II. The uptake of chloroquine by rat fibroblasts and the inhibition of cellular protein degradation and cathepsin B1. J Cell Biol 1974;63:430-440
7. Ehrhardt S, Mockenhaupt FP, Eggelte TA, et al. Chloroquine blood concentrations and molecular markers of chloroquine-resistant Plasmodium falciparum in febrile children in northern Ghana. Trans R Soc Trop Med Hyg 2003;97:697-701
8. Khoury H, Trinkaus K, Zhang MJ, et al. Hydroxychloroquine for the prevention of acute graft-versus-host disease after unrelated donor transplantation. Biol Blood Marrow Transplant 2003;9:714-721
9. Vyas JM, Van der Veen AG, Ploegh HL. The known unknowns of antigen processing and presentation. Nat Rev Immunol 2008;8:607-618
10. Cansu DU, Korkmaz C. Hypoglycaemia induced by hydroxychloroquine in a non-diabetic patient treated for RA. Rheumatology 2008;47:378-379
11. Gerstein HC, Thorpe KE, Taylor DW, Haynes RB. The effectiveness of hydroxychloroquine in patients with type 2 diabetes mellitus who are refractory to sulfonylureas-a randomized trial. Diabetes Res Clin Pract 2002;55:209-219
12. Li C, Zhang S, Shu C. Effects of chloroquine on insulin sensitivity in insulin-resistant rats. Zhonghua Yi Xue Za Zhi Natl Med J China 1999;79:867-869
13. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus Suppl 1996;1:S16-22
14. Powrie JK, Shojaee-Moradic F, Watts GF, et al. Effects of chloroquine on the dyslipidemia of non-insulin dependent diabetes mellitus. Metabolism 1993;42:415-419
15. Shojana K, Koehler BF, Elliot T. Hypoglycemia induced by hydroxychloroquine in a type 2 diabetic treated for polyarthritis. J Rheumatol 1999;1:195-196
16. Wallace DJ. The use of chloroquine and hydroxychloroquine for non-infectious diseases other than rheumatoid arthritis or lupus: a critical review. Lupus Suppl 1996;1:S59-64
17. Burner TW, Rosenthal AK. Diabetes and rheumatic diseases. Curr Opin Rheumatol 2009;21:50-54
18. Avouac J, Allanore Y. Cardiovascular risk in rheumatoid arthritis: effects of anti-TNF drugs. Expert Opin Pharmacother 2008;9:1121-1128
19. Guest CB, Park MJ, Johnson DR, Freund GG. The implication of proinflammatory cytokines in type 2 diabetes. Front Biosci 2008;13:5187-5194
20. Heilbronn LK, Campbell LV. Adipose tissue macrophages, low grade inflammation and insulin resistance in human obesity. Curr Pharm Des 2008;14:1225-1230
21. Ohmuraya M, Yamamura K. Autophagy and acute pancreatitis: a novel autophagy theory for trypsinogen activation. Autophagy 2008;4:1060-1062
22. Uysal KT, Wiesbrock SM, Marino MW, Hotamisligil GS. Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function. Nature 1997;389:610-614
23. Wasko MC, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with rheumatoid arthritis. JAMA 298:187-193
24. Moller DE. Potential role of TNF-alpha in the pathogenesis of insulin resistance and type-2 diabetes. Trends Endocrinol Metab 2000;11:212-217
25. Popa C, Netea MG, van Riel PL, et al. The role of TNF-alpha in chronic inflammatory conditions, intermediary metabolism, and cardiovascular risk. J Lipid Res 2007;48:751-762
26. Guicciardi ME, Miyoshi H, Bronk SF, Gores GJ. Cathepsin B knockout mice are resistant to tumor necrosis factor-alpha mediated hepatocyte apoptosis and liver injury: implications for therapeutic applications. Am J Pathol 2001;159:2045-2054
27. Scarpello JH, Howlett HC. Metformin therapy and clinical uses. Diab Vasc Dis Res 2008;5:157-167
28. Papanas N, Maltezos E. Oral antidiabetic agents: anti-atherosclerotic properties beyond glucose lowering? Curr Pharm Des 2009;15:3179-3192
29. LeBel O, Maris T, Duval H, Wuest JD. A practical guide to arylbiguanides: synthesis and structural characterization Can J Chem 2005;83:615-625
30. Prugnard E, Noel M. Chemistry and structure--activity relationships of biguanides. Handb Exp Pharmacol 1995;119:263-282
31. Brown CL, Whitehouse MW, Tiekink ERT, Bushell GR. Colloidal metallic gold is not bio-inert. Inflammopharmacology 2008;16:133-137
32. Fricker SP, Mosi RM, Cameron BR, et al. Metal compounds for the treatment of parasitic diseases. J Inorg Biochem 2008;102:1839-1845
33. Gunatilleke SS, de Oliveira CA, McCammon JA, Barrios AM. Inhibition of cathepsin B by Au(I) complexes: a kinetic and computational study. J Biol Inorg Chem 2008;13:555-561
34. Sweeney D, Raymer ML, Lockwood TD. Antidiabetic and antimalarial biguanide drugs are metal-interactive antiproteolytic agents. Biochem Pharmacol 2003;66:663-677
35. Lockwood TD. Cys--His proteases are among the wired proteins of the cell. Arch Biochem Biophys 2004;432:12-24
36. Dell'Aglio DM, Perino LJ, Kazzi Z, et al. Acute metformin overdose: examining serum pH, lactate level, and metformin concentrations in survivors versus nonsurvivors: a systematic review of the literature. Ann Emerg Med 2009;54:818-823
37. Lockwood TD. Redox-dependent and redox-independent subcomponents of protein degradation in perfused myocardium. Am J Physiol 1999;276:E945-954
38. Thorne DP, Lockwood TD. Four proteolytic processes of myocardium, one insensitive to thiol reactive agents and thiol protease inhibitor. Am J Physiol 1993;265:E10-19
39. Falchuk KH, Hilt KL, Vallee BL. Determination of zinc in biological samples by atomic absorption spectrometry. Methods Enzymol 1988;158:422-434
40. Kazi TG, Afridi HI, Kazi N, et al. Copper, chromium, manganese, iron, nickel, and zinc levels in biological samples of diabetes mellitus patients. Biol Trace Elem Res 2008;122:1-18
41. Levine AS, McClain CJ, Handwerger BS, et al. Tissue zinc status of genetically diabetic and streptozotocin-induced diabetic mice. Am J Clin Nutr 1983;37:382-386
42. Lu J, Stewart AJ, Sadler PJ, et al. Albumin as a zinc carrier: properties of its high-affinity zinc-binding site. Biochem Soc Trans 2008;36(Pt 6):1317-1321
43. Frlan R, Gobec S. Inhibitors of cathepsin B. Curr Med Chem 2006;13:2309-2327
44. Li L, Mamputu JC, Wiernsperger N, Renier G. Signaling pathways involved in human vascular smooth muscle cell proliferation and matrix metalloproteinase-2 expression induced by leptin: inhibitory effect of metformin. Diabetes 2005;54:2227-2234
45. Ha SD, Martins A, Khazaie K, et al. Cathepsin B is involved in the trafficking of TNF-alpha-containing vesicles to the plasma membrane in macrophages. J Immunol 2008;181:690-697
46. Halangk W, Lerch MM, Brandt-Nedelev B, et al. Role of cathepsin B in intracellular trypsinogen activation and the onset of acute pancreatitis. J Clin Invest 2000;106:773-781
47. Maehr R, Mintern JD, Herman AE, et al. Cathepsin L is essential for onset of autoimmune diabetes in NOD mice. Clin Invest 2005;115:2934-2943
48. Van Acker GJ, Saluja AK, Bhagat L, et al. Cathepsin B inhibition prevents trypsinogen activation and reduces pancreatitis severity. Am J Physiol Gastrointest Liver Physiol 2002;283:G794-800
49. Masini M, Bugliani M, Lupi R, et al. Autophagy in human type 2 diabetes pancreatic beta cells. Diabetologia 2009;52:1083-1086
50. Lockwood TD. Responsiveness of parasite Cys His proteases to iron redox. Parasitol Res 2006;100:175-181
51. Akazawa Y, Mott JL, Bronk SF, et al. Death receptor 5. internalization is required for lysosomal permeabilization by TRAIL in malignant liver cell lines. Gastroenterology 2009;136:2365-2376
52. Li JH, Pober JS. The cathepsin B death pathway contributes to TNF plus IFN-gamma-mediated human endothelial injury. J Immunol 2005;175:1858-1866
53. Li JH, D'Alessio A, Pober JS. Lipopolysaccharide can trigger a cathepsin B-dependent programmed death response in human endothelial cells. Am J Pathol 2009;175:1124-1135
54. Pratt MR, Sekedat MD, Chiang KP, Muir TW. Direct measurement of cathepsin B activity in the cytosol of apoptotic cells by an activity-based probe. Chem Biol 2009;16:1001-1012
55. Taha TA, Kitatani K, Bielawski J, et al. Tumor necrosis factor induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism. J Biol Chem 2005;280:17196-17202
56. Yan BZ, Wang W, Chen LY, et al. Role of cathepsin B-mediated apoptosis in fulminant hepatic failure in mice. World J Gastroenterol 2009;15:1231-1236
57. Turk V, Stoka V, Turk D. Cystatins: biochemical and structural properties, and medical relevance. Front Biosci 2008;13:5406-5420
58. Joensuu T, Lehesjoki AE, Kopra O. Molecular background of EPM1-Unverricht-Lundborg disease. Epilepsia 2008;49:557-563
59. Kaasik A, Kuum M, Aonurm A, et al. Seizures, ataxia, and neuronal loss in cystatin B heterozygous mice. Epilepsia 2007;48:752-757
60. Becker JS, Mounicou S, Zoriy MV, et al. Analysis of metal-binding proteins separated by non-denaturating gel electrophoresis using matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) and laser ablation inductively coupled plasma mass spectrometry (LA-ICP-MS). Talanta 2008;76:1183-1188
61. Pungercar JR, Caglic D, Sajid M, et al. Autocatalytic processing of procathepsin B is triggered by proenzyme activity. FEBS J 2009;276:660-668
62. Redzynia I, Ljunggren A, Abrahamson M, et al. Displacement of the occluding loop by the parasite protein, chagasin, results in efficient inhibition of human cathepsin B. J Biol Chem 2008;283:22815-22825
63. Cousins RJ, Liuzzi JP, Lichten LA. Mammalian zinc transport, trafficking, and signals. J Biol Chem 2008;281:24085-24089
64. Devirgiliis C, Zalewski PD, Perozzi G, Murgia C. Zinc fluxes and zinc transporter genes in chronic diseases. Mutat Res 2007;622:84-93
65. Murakami M, Hirano T. Intracellular zinc homeostasis and zinc signaling. Cancer Sci 2008;99:1515-1522
66. Wellenreuther G, Cianci M, Tucoulou R, et al. The ligand environment of zinc stored in vesicles. Biochem Biophys Res Commun 2009;380:198-203
67. Dong XP, Cheng X, Mills E, et al. The type IV mucolipidosis-associated protein TRPML1 is an endolysosomal iron release channel. Nature 2008;455:992-996
68. Bevan AP, Krook A, Tikerpae J, et al. Chloroquine extends the lifetime of the activated insulin receptor complex in endosomes. J Biol Chem 1997;272:833-840
69. Blazar BR, Whitly CB, Kitabchi AE, et al. In vivo chloroquine-induced inhibition of insulin degradation in a diabetic patient with severe insulin resistance. Diabetes 1984;33:1133-1137
70. Sakurai H, Adachi Y. The pharmacology of the insulinomimetic effect of zinc complexes. Biometals. 2005;8:319-323
71. Emani J, Gerstein HC, Pasutto FM, Janmali F. Insulin-sparing effect of hydroxychloroquine in diabetic rats is concentration dependent. Can J Physiol Pharmacol 1999;77:118-123
72. Valensi P, Behar A, Cohen-Boulakia F, et al. In-vivo kinetics of 123 iodine-labelled insulin in skeletal muscle of patients with type-2 diabetes: effects of metformin. Diabet Metab 2002;28:95-103
73. Zhang Z, Radziuk J. Inverse relationship between peripheral insulin removal and action: studies with metformin. Am J Physiol Endocrinol Metab 2001;281:E1240-8 (Pubitemid 34001199)
74. Salpeter S, Greyber E, Pasternak G, Salpeter E. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 2006;1:CD002967
75. Mayer S, Daigle DM, Brown ED, et al. An expedient and facile one-step synthesis of a biguanide library by microwave irradiation coupled with simple product filtration. Inhibitors of dihydrofolate reductase. J Comb Chem 2004;6:776-782